Compare D R Horton Inc (DHI) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Neurocrine Biosciences Inc — how do they compare? D R Horton Inc trades at $150.79 (market cap $42.18B), while Neurocrine Biosciences Inc trades at $151.61 (market cap $16.46B). The key difference: D R Horton Inc is far larger — about 2.6× Neurocrine Biosciences Inc's market cap, and D R Horton Inc pays a 1.19% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| DHI | NBIX | |
|---|---|---|
Market Cap | $42.18B | $16.46B |
Sector | Consumer Cyclical | Health |
52-Week High | $184.04 | $185.50 |
52-Week Low | $132.53 | $123.10 |
Enterprise Value | $47.28B | $16.48B |
Dividend Yield | 1.19% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
